---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-029841"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-07-28T12:20:37+00:00"
generated_at: "2026-07-28T12:25:17.709880+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools sells Mass Cytometry business to Multiplex Bio, receives $30M from Illumina buyout

## Summary
- Sells Mass Cytometry business (CyTOF/Hyperion) to Multiplex Bio for up to $10M; provides up to $10M working capital loan.
- Received ~$30M cash from Illumina to waive 2026 earnout and terminate royalty/license agreements from SomaLogic acquisition.
- Early termination of HSR waiting period for Treeline merger; merger expected to close by end of 2026.
- Multiplex Bio led by industry veterans; business to continue under Standard BioTools brand.
- Transactions subject to stockholder approval and customary conditions; expected to close concurrently with Treeline merger.

## SEC filing metadata
- accession: 0001140361-26-029841
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-07-28T12:20:37+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/0001140361-26-029841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/ef20078901_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-029841
- JSON: https://secwatch.observer/filing/0001140361-26-029841.json
- Plain text: https://secwatch.observer/filing/0001140361-26-029841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.